Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...
Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results